MRNA:NSD-Moderna, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 61.58

Change

+0.49 (+0.80)%

Market Cap

USD 22.86B

Volume

7.59M

Average Target Price

USD 65.60 (+6.53%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Moderna, Inc., a clinical stage biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases. As of February 15, 2019 the company had 11 programs in clinical trials and a total of 20 development candidates in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca, Merck & Co., Vertex Pharmaceuticals, Biomedical Advanced Research and Development Authority, Defense Advanced Research Projects Agency, and Bill & Melinda Gates Foundation; and a research collaboration with Harvard University. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of mRNA-1273, a COVID-19 vaccine; and Catalent for fill-finish manufacturing of its COVID-19 vaccine candidate. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-07-08 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

-3.14 (-1.05%)

USD76.11B 50.45 37.87
REGN Regeneron Pharmaceuticals, Inc

-0.54 (-0.08%)

USD65.50B 31.28 21.67
SGEN Seattle Genetics, Inc

-0.61 (-0.35%)

USD30.38B N/A N/A
ALXN Alexion Pharmaceuticals, Inc

-4.46 (-3.97%)

USD23.85B 10.60 9.11
INCY Incyte Corporation

-0.38 (-0.35%)

USD23.62B 47.64 35.20
BMRN BioMarin Pharmaceutical Inc

+0.75 (+0.59%)

USD23.14B 201.24 120.72
GMAB Genmab A/S

+0.86 (+2.50%)

USD22.35B 60.04 6.37
ALNY Alnylam Pharmaceuticals, Inc

+0.42 (+0.26%)

USD18.21B N/A N/A
BNTX BioNTech SE

-1.78 (-2.57%)

USD15.72B -99,999.99 N/A
BGNE BeiGene, Ltd

+7.51 (+3.82%)

USD15.64B N/A N/A

ETFs Containing MRNA

Symbol Name Weight Mer Price(Change) Market Cap
CNCR Loncar Cancer Immunothera.. 11.01 % 0.79 %

+0.39 (+1.42%)

USD0.04B
BBH VanEck Vectors Biotech ET.. 7.33 % 0.35 %

+0.80 (+0.48%)

USD0.47B
IPO Renaissance IPO ETF 4.69 % 0.60 %

+1.24 (+2.90%)

USD0.04B
BTEC Principal Healthcare Inno.. 4.52 % 0.42 %

+0.74 (+1.63%)

USD0.09B
XBI SPDR S&P Biotech ETF 4.01 % 0.35 %

+1.73 (+1.50%)

USD4.91B
IDNA iShares Genomics Immunolo.. 3.87 % 0.47 %

+0.44 (+1.13%)

USD0.11B
PTH Invesco DWA Healthcare Mo.. 3.75 % 0.60 %

+1.61 (+1.26%)

USD0.38B
RBUS Nationwide Risk-Based U.S.. 3.19 % 0.30 %

N/A

USD0.11B
BBC Virtus LifeSci Biotech Cl.. 3.00 % 0.79 %

+0.73 (+1.68%)

USD0.05B
IBB iShares Nasdaq Biotechnol.. 2.57 % 0.47 %

+0.75 (+0.54%)

USD8.84B
AIEQ AI Powered Equity ETF 2.47 % 0.87 %

+0.15 (+0.52%)

USD0.09B
BTEE:LSE iShares Nasdaq US Biotech.. 2.46 % 0.35 %

-0.09 (-1.40%)

USD0.22B
BTEK:LSE iShares Nasdaq US Biotech.. 2.46 % 0.35 %

-0.07 (-1.42%)

USD0.22B
FLAG FLAG-Forensic Accounting .. 1.92 % 1.44 %

N/A

USD4.83M
FNY First Trust Mid Cap Growt.. 0.92 % 0.70 %

+0.66 (+1.36%)

USD0.30B
SCHA Schwab U.S. Small-Cap ETF 0.75 % 0.04 %

+0.52 (+0.80%)

USD7.99B

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 214.83% 94% A 96% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 214.83% 94% A 96% A
Trailing 12 Months  
Capital Gain 314.68% 93% A 96% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 314.68% 93% A 96% A
Trailing 5 Years  
Capital Gain 14,554.93% 99% A+ 100% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 14,554.93% 99% A+ 100% A+
Average Annual (5 Year Horizon)  
Capital Gain 757.74% 99% A+ 99% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 757.74% 99% A+ 99% A+
Risk Return Profile  
Volatility (Standard Deviation) 1,073.55% 1% F 1% F
Risk Adjusted Return 70.58% 96% A 77% C+
Market Capitalization 22.86B 99% A+ 96% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 13.25 14% F 9% F
Price / Cash Flow Ratio -49.81 95% A 94% A
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -32.76% 80% B- 29% F
Return on Invested Capital -40.30% 72% C- 22% F
Return on Assets -17.26% 76% C 22% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 0.95 70% C- 73% C
Short Percent 10.29% 28% F 21% F
Beta 1.21 67% D+ 46% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector